Comparative Pharmacology
Head-to-head clinical analysis: PALYNZIQ versus REVCOVI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PALYNZIQ versus REVCOVI.
PALYNZIQ vs REVCOVI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PALYNZIQ (pegvaliase-pqpz) is a recombinant phenylalanine ammonia lyase conjugated to polyethylene glycol. It converts phenylalanine to trans-cinnamic acid and ammonia, reducing blood phenylalanine levels in patients with phenylketonuria.
Recombinant adenosine deaminase (ADA) enzyme replacement therapy; degrades adenosine and deoxyadenosine, reducing toxic metabolites and restoring immune function.
2.4 mg subcutaneously once daily.
25 mg/kg body weight administered intramuscularly once weekly.
None Documented
None Documented
Approximately 60–80 hours (terminal half-life); supports weekly dosing regimen.
Terminal elimination half-life is approximately 3-6 months (mean ~100 days) in patients with PEG-ADA deficiency; clinical context: sustained enzyme replacement allows weekly or biweekly dosing.
Renal (predominantly as intact pegylated enzyme); less than 5% fecal. No active metabolites.
Renal excretion of unchanged drug and metabolites: approximately 100% eliminated renally; no significant biliary/fecal elimination.
Category C
Category C
Enzyme Replacement Therapy
Enzyme Replacement Therapy